Codexis (CDXS) Surpasses Q4 Expectations for Earnings and Revenue

Codexis Reports Strong Quarterly Earnings

Codexis (CDXS) announced quarterly earnings of $0.11 per share, significantly exceeding the Zacks Consensus Estimate of $0.01 per share. In contrast, the company reported a loss of $0.13 per share during the same period last year. These results exclude one-time items.

This quarter's performance marks an earnings surprise of 2,100%. In the previous quarter, analysts had anticipated a loss of $0.15 per share, but Codexis actually posted a loss of $0.22 per share, resulting in a negative surprise of 46.67%.

Looking at the past four quarters, Codexis has outperformed consensus earnings per share estimates twice.

Operating within the Medical - Biomedical and Genetics sector, Codexis generated $38.92 million in revenue for the quarter ending December 2025, surpassing the Zacks Consensus Estimate by 1.61%. This is a notable increase from $21.46 million in revenue reported a year earlier. Over the last year, the company has beaten revenue expectations in two quarters.

The immediate impact on Codexis's share price will likely depend on management's guidance and insights shared during the earnings call, as well as future earnings projections.

Since the start of the year, Codexis shares have declined approximately 23.9%, compared to a 0.9% drop in the S&P 500 index.

What Lies Ahead for Codexis?

Although Codexis has lagged behind the broader market so far this year, investors are now focused on what the future holds for the stock.

While there is no simple answer, one key indicator for investors is the company's earnings outlook. This includes not only current consensus estimates for upcoming quarters, but also recent changes in those expectations.

Research indicates that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or utilize established tools such as the Zacks Rank, which has a strong track record of leveraging earnings estimate trends.

Prior to this earnings announcement, estimate revisions for Codexis were mixed. While the latest results may influence future revisions, the current outlook gives Codexis a Zacks Rank #3 (Hold), suggesting the stock is likely to perform in line with the market in the near term. For a list of Zacks #1 Rank (Strong Buy) stocks, click here.

It remains to be seen how analyst estimates for the next quarters and the current fiscal year will evolve. Presently, the consensus estimate for the next quarter is an EPS of -$0.02 on $19.02 million in revenue, and for the full year, an EPS of -$0.33 on $70.17 million in revenue.

Investors should also consider the broader industry outlook, as it can significantly influence stock performance. The Medical - Biomedical and Genetics industry currently ranks in the bottom 42% among over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperform the bottom half by more than two to one.

Another company in the same sector, Orchestra BioMed Holdings, Inc. (OBIO), has not yet released results for the quarter ending December 2025.

Orchestra BioMed Holdings is projected to report a quarterly loss of $0.38 per share, reflecting an 11.6% improvement year-over-year. The consensus EPS estimate for this period has remained steady over the past month.

The company's revenue is expected to reach $0.79 million, representing a 216% increase from the same quarter last year.

Is Codexis, Inc. (CDXS) a Good Investment?

Before making an investment decision on Codexis, Inc. (CDXS), you may want to explore the top stock picks for the next 30 days. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent research and analytical tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500's performance from January 1, 1988 through May 6, 2024.

For the latest stock recommendations from Zacks Investment Research, you can download the 7 Best Stocks for the Next 30 Days. Get your free report here.